FDA Eliminates Barrier to Clozapine, Plans to End REMS Program
(MedPage Today) — The FDA no longer expects prescribers, pharmacies, and patients to participate in the risk evaluation and mitigation strategy (REMS) program for the antipsychotic clozapine, the agency announced this week.
Following the advice…
